[heavyweight] ravidavir, an innovative hepatitis C drug, was included in the guidelines for hepatitis C treatment by the World Health Organization

August 6, 2018 / Meitong news agency / -- geley Pharmaceutical Co., Ltd (geley pharmaceutical 1672 HK) announced yesterday that its second innovative hepatitis C drug, ravidavir (RDV), as the future pan genotype direct antiviral drug (DAA), was included in the latest version of hepatitis C treatment guidelines by the World Health Organization (who) in July 2018 On August 1, the application for listing of new drug of geliravidavir was accepted by the State Drug Administration Ravidavir is a new generation of Pan genotype NS5A inhibitor developed by Geli Up to now, three phase III clinical studies have been completed at home and abroad, and more than 1000 subjects have been enrolled The results of phase II / III clinical trials in China show that the first all oral hepatitis C treatment plan in China, which is composed of ravidavir and gonovir (DNV), has a 12 week cure rate of 99% (svr12), and is not affected by the baseline NS5A resistance Dr Wu JINZI, the founder, chairman and President of Geli, said, "I'm glad that ravidavir, as a pan gene DAA, was included in the WHO guidelines for hepatitis C treatment just when the application for new drug listing was submitted and accepted This shows that the excellent efficacy and safety of ravidavir have not only been recognized by the international academic field, but also been recommended by the international authoritative public health institutions "